Eli Lilly’s Mounjaro Approved by China’s NMPA for Obstructive Sleep Apnea in Obese Adults
US pharma giant Eli Lilly & Co. (NYSE: LLY) announced that it has received a...
Product approvals
Sino Biopharmaceutical’s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment
China’s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the...
Thermo Fisher’s Oncomine Dx Express Test Approved by FDA as Companion Diagnostic for Dizal’s Zegfrovy
US-based Thermo Fisher Scientific Inc. (NYSE: TMO) announced that it has received marketing approval from...
Jiangsu Hengrui Announces NMPA Approval for Miebo in Dry Eye Disease Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...
Hangzhou Jiuyuan Announces NMPA Approval for Generic Doptelet in Thrombocytopenia Treatmen
Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced that it has received marketing approval...
Betta Pharmaceuticals’ Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from...
Regeneron’s Lynozyfic Granted FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) announced that it has received accelerated approval from the...
Sumitomo Pharma’s Xenleta Approved in China for Community-Acquired Pneumonia Treatment
Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for...
BEBT-908 Receives Conditional NMPA Approval for Relapsed/Refractory DLBCL
Guangzhou BeBetter Medicine Technology Co., Ltd’s first-in-class HDAC/PI3Kα dual-targeted inhibitor BEBT-908 has received conditional approval...
Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that the U.S. Food and Drug Administration...
Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer
China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval...
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...
Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...
HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...
Hengrui Pharmaceuticals’ Aihengping Gains NMPA Approval for Regional Analgesia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...
Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...
Hengrui Pharmaceuticals Gains NMPA Approval for Aisuda in Severe Alopecia Areata
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received additional indication approval from the...
MicroPort NeuroTech’s NUMEN Nest Gains FDA Marketing Approval
China-based MicroPort NeuroTech Limited (HKG: 2172) announced that its NUMEN Nest, an enhanced version of...
BMS Secures FDA Approval for Updated Labels of Breyanzi and Abecma
US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the US Food and Drug Administration...